Language
繁體中文
簡體中文
English
關於安成About Us
Company Profile
Management Team
Milestones
Plant & Quality
Join Us
Contact
Products
研究與發展Research & Development
High Barrier Generics
投資人關係
Shareholder Services
Corporate Governance
Unaudited Monthly Sales
Financial Report
Shareholder Contacts
新聞發佈News & Media
News
Announcement
News
Announcement
Home > News & Media > News
Communication starts here.
2016.09
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2015.09
TWi Pharmaceuticals Issues GDR and raised NT$ 2.83 Billion
2015.09
TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO
2015.08
TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
2015.08
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
2015.07
TWi Pharmaceuticals Launches Generic MEGACE ES® After Favorable Decision In Patent Suit
2015.06
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Guanfacine HCl ER Tablet
2015.05
TWi Pharmaceuticals Announced the promotion of R&D EVP Jianbo Xie as COO
2015.04
TWi Announces Settlement with Takeda on Dexilant® Litigation
2015.04
TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.
Pages:
1
-
2
-
3
-
4
-
5
« Pre
·
Next »